Friday, 13 July 2018

U.S. court denies Jazz Pharma bid to revive patents on narcolepsy drug

A U.S. appeals court on Friday ruled invalid patents owned by Jazz Pharmaceuticals PLC covering its narcolepsy drug Xyrem, opening the door for Amneal Pharmaceuticals Inc to launch a generic version of the medicine.


No comments:

Post a Comment